1	Microbiota-Short Chain Fatty Acid Relationships Underlie Clinical Heterogeneity and
2	Identify Key Microbial Targets in Irritable Bowel Syndrome (IBS)
3	<sup>1</sup> Andrea Shin,* <sup>2</sup> Yue Xing, <sup>3</sup> Mohammed Rayyan Waseem, <sup>3</sup> Robert Siwiec, <sup>3</sup> Toyia James-
4	Stevenson, <sup>3</sup> Nicholas Rogers, <sup>3</sup> Matthew Bohm, <sup>3</sup> John Wo, <sup>3</sup> Carolyn Lockett, <sup>3</sup> Anita Gupta,
5	<sup>3</sup> Jhalka Kadariya, <sup>4</sup> Evelyn Toh, <sup>3</sup> Rachel Anderson, <sup>5</sup> Huiping Xu, <sup>2</sup> Xiang Gao*
6	(*co-corresponding authors)
7	from the <sup>1</sup> Vatche and Tamar Manoukian Division of Digestive Diseases at the University of
8	California Los Angeles, Los Angeles, CA; the <sup>2</sup> Department of Medicine at Stritch School of
9	Medicine, Loyola University Chicago, Chicago, IL; the <sup>3</sup> Division of Gastroenterology and
10	Hepatology, Indiana University School of Medicine, Indianapolis, IN; the Department of
11	Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN; and
12	the <sup>5</sup> Department of Biostatistics and Health Data Science, Indiana University School of
13	Medicine, Indianapolis, Indiana
14	Short Title: Microbiota-SCFA Associations in IBS
15	Acknowledgements: The authors would like to thank the Mayo Clinic Department of
16	Laboratory Medicine and Pathology and Purdue University Metabolite Profiling Facility for their
17	collaboration and assistance with quantification of stool bile acids and short chain fatty acids.
18	Word Count: 5076 excluding abstract, references, table/figure legends).
19	Funding: AS has received funding from NIDDK K23DK122015 and R03DK132446.
20	Abbreviations: ALR=additive log-ratio; BAM=bile acid malabsorption; CTT=colonic transit
21	time; gDNA=genomic DNA; GI=gastrointestinal; GLM=generalized linear model; GMM=gut

2

22	metabolic module; IBS=irritable bowel syndrome; IBS-D=IBS with diarrhea; IBS-C IBS with
23	constipation; KEGG=Kyoto Encyclopedia of Genes and Genomics; KO=KEGG Orthogroup;
24	LC-MS=liquid chromatography-mass spectrometry; SCFA=short chain fatty acids
25	Disclosures: AS serves on Ardelyx Scientific Communications Advisory Board for irritable
26	bowel syndrome with constipation.
27	Author Contributions: Developing study concept: AS. Planning study design: AS, HX, XG.
28	Participant recruitment: AS, MRW, RS, TJS, NR, MB JW, CL, AG, JK, RA. Data collection and
29	study procedures: AS, MRW, CL, AG, JK, ET. Data Management: AS, YX, MRW, CL, JK, HX,
30	XG. Data Analysis and Interpretation: YX, XG. Drafting the manuscript: AS, XG. Critically
31	revising the manuscript: MRW, RS, TJS, NR, MB, JW, ET, HX.
32	Data Transparency Statement: Microbiome sequencing reads are deposited into NCBI with
33	accession number SUB13882354. The data that support the findings of this study are available
34	upon reasonable request from the corresponding author.
35	Correspondence:
36	Andrea S. Shin, M.D., M.Sc.; G. Oppenheimer Center for Neurobiology of Stress and
37	Resilience; David Geffen School of Medicine at UCLA; 10833 Le Conte Avenue, CHS 42-210;
38	Los Angeles, CA 90095-7378; Tel: (310) 206-0192; Fax: (310) 825-1919
39	Xiang Gao, PhD.; Department of Medicine; Stritch School of Medicine at Loyola University
40	Chicago; 2160 S. Frist Avenue; Maywood, IL 60153; Tel: (708) 327-9021

3

## 42 ABSTRACT

Background: Identifying microbial targets in irritable bowel syndrome (IBS) and other 43 44 disorders of gut-brain interaction (DGBI) is challenging due to the dynamic nature of 45 microbiota-metabolite-host interactions. SCFA are key microbial metabolites that modulate intestinal homeostasis and may influence IBS pathophysiology. We aimed to assess microbial 46 47 features associated with short chain fatty acids (SCFA) and determine if features varied across IBS subtypes and endophenotypes. Among 96 participants who were screened, 71 completed the 48 study. We conducted in-depth investigations of stool microbial metagenomes, stool SCFA, and 49 50 measurable IBS traits (stool bile acids, colonic transit, stool form) in 41 patients with IBS (IBS 51 with constipation [IBS-C] IBS with diarrhea [IBS-D]) and 17 healthy controls. We used partial 52 canonical correspondence analyses (pCCA), conditioned on transit, to quantify microbe-SCFA 53 associations across clinical groups. To explore relationships between microbially-derived SCFA 54 and IBS traits, we compared gut microbiome-encoded potential for substrate utilization across 55 groups and within a subset of participants selected by their stool characteristics as well as stool 56 microbiomes of patients with and without clinical bile acid malabsorption. 57 **Results:** Overall stool microbiome composition and individual taxa abundances differed between 58 clinical groups. Microbes-SCFA associations differed across groups and revealed key taxa including Dorea sp. CAG:317 and Bifidobacterium pseudocatenulatum in IBS-D and 59

60 *Akkermansia muciniphila* and *Prevotella copri* in IBS-C that that may drive subtype-specific

61 microbially-mediated mechanisms. Strongest microbe-SCFA associations were observed in IBS-

- 62 D and several SCFA-producing species surprisingly demonstrated inverse correlations with
- 63 SCFA. Fewer bacterial taxa were associated with acetate to butyrate ratios in IBS compared to
- 64 health. In participants selected by stool form, we demonstrated differential abundances of

4

- across groups. SCFA-producing taxa were reduced in IBS-D patients with BAM.
- 67 Conclusion Keystone taxa responsible for SCFA production differ according to IBS subtype and
- traits and the IBS microbiome is characterized by reduced functional redundancy. Differences in
- 69 microbial substrate preferences are also linked to bowel functions. Focusing on taxa that drive
- 70 SCFA profiles and stool form may be a rational strategy for identifying relevant microbial targets
- 71 in IBS and other DGBI.
- 72 Key words: colonic microflora, bile acid metabolism, gut-brain interaction, functional
- 73 gastrointestinal disorder, microbiome

#### 5

## 75 **INTRODUCTION**

Irritable bowel syndrome (IBS) is a burdensome disorder of gut-brain interaction with an
estimated global prevalence rate of 5-10%.<sup>1</sup> Pathophysiological mechanisms of IBS include
disturbances in motility or transit, altered intestinal secretion, impaired intestinal permeability,
immune cell reactivity, visceral hypersensitivity, and dysregulated neural signaling and/or central
processing.<sup>2</sup> Despite advancements in the understanding of IBS pathogenesis, diagnostic and
therapeutic IBS biomarkers are limited.

Accumulating evidence suggests that the gastrointestinal (GI) microbiome is associated 82 83 with risk of IBS and may also mediate many of the mechanisms that underlie symptoms including altered motility,<sup>3,4</sup> barrier dysfunction,<sup>5</sup> immune activation,<sup>6,7</sup> signaling along the 84 brain-gut axis,<sup>8</sup> and visceral sensation.<sup>9</sup> Characterization of microbial composition in IBS has 85 suggested decreased microbial diversity, reduced temporal stability, or changes in the relative 86 abundance of specific bacteria in patients with IBS.<sup>10, 11</sup> However, these findings have not been 87 sufficiently consistent across studies to establish a clear microbial profile in IBS and gaps in our 88 understanding of the functional microbiome persist. Integrating complementary strategies in the 89 investigation of microbial metabolites will be crucial for gathering actionable insights into the 90 91 impact of the microbiome in IBS.

Atypical profiles of microbial metabolites including luminal bile acids<sup>12, 13</sup> and short chain fatty acids (SCFA) have been described in some patients with IBS.<sup>14, 15</sup>Bile acid malabsorption (BAM) is recognized as a mechanistic IBS subtype that can be assessed through several diagnostic methods including measurement of total or primary stool bile acids.<sup>13</sup> Studies have demonstrated BAM to be associated with physiological traits, symptoms, and quality of life.<sup>16-19</sup> Recently, researchers have examined microbial contributions to BAM in IBS to report

6

98	alterations such as enrichment of <i>Clostridia</i> bacteria including <i>C. scindens</i> , <sup>20</sup> lower microbial
99	alpha diversity, higher Firmicutes to Bacteroidetes ratio, <sup>19</sup> and presence of endoscopically visible
100	biofilms correlating with overgrowth of <i>Escherichia coli</i> and <i>Ruminococcus gnavus</i> . <sup>21</sup>

101 SCFA are produced by anaerobic fermentation of dietary fibers and resistant starch that enter the colon and regulate intestinal homeostasis and physiology.<sup>22</sup> Compared to bile acids, the 102 103 role of SCFA in IBS is less well understood. Studies of stool SCFA in IBS have yielded variable 104 results, which may be related to the heterogeneity of the IBS patient populations and multiple pathways through which SCFA may modulate intestinal physiology. Therefore, while stool 105 106 SCFA are unlikely to serve as categorical IBS biomarkers, they may provide critical insights into 107 the pathophysiological mechanisms that underlie IBS symptoms or serve as a tool for identifying metabolically relevant microbial targets. Studies<sup>15, 23</sup> that have assessed stool SCFA in distinct 108 109 IBS subgroups have reported more consistent associations of stool SCFA with IBS subtypes as 110 well as correlations of stool SCFA with measurable IBS traits such as colonic transit, bowel functions, and bile acid excretion.<sup>23-25</sup> Despite these reports, the intercorrelation between SCFA 111 112 and transit time complicates the assessment of whether SCFA profiles represent the metabolic capacity of the resident microbiome. It remains unclear if studying the relationships between the 113 microbiome and excreted SCFA is clinically informative. Recent work<sup>26</sup> has suggested that 114 individual or keystone taxa, rather than complex ecological communities, could drive changes in 115 SCFA output in response to dietary fiber. Therefore, strategies that isolate major microbial 116 117 features (or keystone taxa) that shape luminal SCFA may serve as a rational method for selecting functionally relevant microbial targets in patients with IBS. To address these questions, we 118 119 conducted an in-depth investigation of GI microbiome composition and function, stool SCFA,

7

and IBS endophenotypes defined according to quantitative traits (transit, bile acids, bowelfunctions) in adults with and without IBS.

#### 122 MATERIALS AND METHODS

123 *Participant Recruitment and Study Design:* The study was approved by the Indiana University

124 Institutional Review Board and the protocol registered within ClinicalTrials.gov

125 (NCT02981888). The study was designed as an observational investigation of stool SCFA, stool

bile acids, colonic transit, and stool microbiota in adults with and without IBS. We enrolled

adults ages 18-65 years of age through the Indiana University Gastroenterology Clinics, the

128 Indiana Clinical and Translational Research Institute Research Registry, and from the local

community. We included individuals with IBS with diarrhea (IBS-D) or IBS with constipation

130 (IBS-C) according to Rome IV criteria<sup>27</sup> and healthy controls with no prior history of GI diseases

131 or symptoms. Detailed eligibility criteria are available in the Supplemental Methods.

*Data Collection:* Study eligibility, medications, medical history, and baseline diet using a food frequency questionnaire<sup>28</sup> were assessed during a screening visit with a study physician. Over a two-week period, data were collected on bowel functions using a standardized bowel pattern diary including the Bristol stool form scale.<sup>29</sup> All participants submitted a 48-hour stool collection collected during the last 2 days of a 4-day 100 g fat diet, consistent with clinically validated methods for identifying BAM. Specimens were refrigerated during the collection period, returned to the research team on ice, and stored at -80°C.

139 *Colonic Transit by Radiopaque Markers:* Participants underwent assessment of colonic transit
 140 time with a previously validated and optimized method using radiopaque markers.<sup>30</sup>

141	Stool SCFA and Bile Acids: Frozen aliquots of stool were shipped to the Metabolite Profiling
142	Facility at Purdue University to measure total and individual SCFA concentrations per mg of dry
143	weight by liquid chromatography-mass spectrometry (LC-MS) using published methods <sup>31</sup> and to
144	the Mayo Clinic Department of Laboratory Medicine and Pathology to measure total and
145	primary stool bile acid levels by high-performance LC-MS through a commercially available,
146	CLIA-approved assay. <sup>16, 32, 33</sup> Individual SCFA of interest included acetate, butyrate, and
147	propionate as these represent the predominant SCFA produced in humans. <sup>34</sup>
148	DNA Extraction, Purification, and Sequencing: Genomic DNA was isolated from stool using the
149	QIAmp® PowerFecal® DNA kit (QIAGEN Inc., Germantown, MD, USA). DNA quality and
150	concentration were on a Qubit fluorometer. Purified DNA underwent library preparation
151	(Nextera XT, Illumina) and paired-end (2x150 bp) sequencing using the NovaSeq v1.5 SP
152	(Illumina, San Diego, CA, USA) to target a sequencing depth of 40M sequences per sample.
153	Metagenomic Data Analysis: Metagenomic sequencing reads were quality filtered and processed
154	for taxonomic profiling using MetaPhlAn3. Additive log-ratio (ALR) transformation was applied
155	to analyze differential taxonomic abundances. Based on the identified microbial taxa from each
156	sample, $\beta$ -diversity indices (e.g., Bray-Curtis dissimilarity) were calculated using the R packages
157	phyloseq and vegan. <sup>35, 36</sup> Functional profiling was conducted using the HUMAnN3 pipeline
158	annotated by KEGG (Kyoto Encyclopedia of Genes and Genomes) orthogroups (KO).
159	Statistical Considerations: We summarized major endpoints of interest: (1) stool microbiome
160	composition, (2) stool SCFA concentrations (total, acetate, propionate, butyrate), total and
161	percent primary stool bile acids, and (3) colonic transit time (overall and segmental). Our
162	primary objective was to quantify the association between microbiome composition and SCFA

9

163 (microbe-SCFA associations) across clinical groups after controlling for transit and to account
164 for the mechanistic heterogeneity that underlies clinical IBS populations.

165 We compared microbial taxa abundances between groups and analyzed associations of 166 taxa abundances with IBS endophenotypes/traits (stool SCFA, stool bile acids, and transit) for 167 the collective cohort and within groups. Associations of microbiome composition with group 168 were assessed using general linear regression models (GLM) adjusted for covariates including 169 age, sex, and BMI. Only high abundant species (relative abundance  $\geq 0.1\%$ ) that were prevalent 170 in  $\geq 2$  specimens within  $\geq 1$  clinical group were considered. Partial Canonical Correspondence 171 Analysis (pCCA) conditioned on transit time was employed to quantify the relationship between 172 the microbiome and stool SCFA in all participants and within clinical groups, using the vegan package in R. The significance of the model was assessed through a permutation test with 999 173 174 iterations. To identify bacteria whose abundances were strongly associated with the stool SCFA 175 concentrations, we focused on those bacteria scattered along the direction of specific SCFA axis 176 in the biplot, within a 60-degree angle centered around the SCFA axis in both positive and 177 negative directions. The strength of association between the bacteria and the SCFA was ranked 178 by projecting of the bacteria species scores onto each SCFA axis in the biplot. Bacteria with 179 projection scores less than 0.5 were excluded from the subsequent analysis.

For exploratory analyses, we analyzed multivariable associations of microbiome composition with clinical BAM among individuals with IBS-D. Relative abundances were used to examine the associations of gene family/pathway abundances across clinical groups. A manually curated gut-metabolic analysis framework<sup>37</sup> was applied to examine KO identifiers associated with carbohydrate degradation, SCFA production or metabolism, and mucin degradation using GLM adjusting for covariates. As stool form<sup>38</sup> has been identified as a strong

10

source of human microbiota variation and closely linked to transit,<sup>39, 40</sup> we further explored
associations of functional potential across groups in a subset of participants who were selected
based on stool form features (i.e. those individuals best representing the stool types within their
respective clinical group according to bowel diary data) using the Kruskal-Wallis test. For
example, we chose the IBS-D and IBS-C participants with the loosest and firmest stool types,
respectively, and controls with consistently normal stool types. For all endpoints, missing values
were excluded from the analysis for that endpoint.

## 193 **RESULTS**

194 *Participant Characteristics*: Among 96 volunteers who underwent screening evaluation, 71

195 completed the study, and 58 participants (Figure 1) with a mean [ $\pm$ SD] age = 35.5 ( $\pm$ 13.8) years

and mean [ $\pm$ SD] BMI = 26.2 [ $\pm$ 7.5] kg/m<sup>2</sup>) were included in the final analysis after excluding

197 those who ineligible (n=16), lost to follow-up (n=9), or and/or did not provide SCFA data

198 (n=13). Baseline clinical characteristics (Table 1) were not significantly different across groups

199 (all p=ns). Comparisons of quantitative traits demonstrated differences in total stool bile acids

and transit between IBS-D and control participants and in total stool SCFA and stool acetate)

201 between IBS and controls Table 2, Figures 2-3.

### 202 <u>Stool microbiome composition differs between IBS and health and between IBS subtypes:</u>

203 Shotgun metagenomic sequencing of stool samples was undertaken to obtain total of 3.1 Gb of

sequence data after removal of contaminants with an average of 37.6 million paired-end reads

- 205 per sample (deposited into NCBI with accession number SUB13882354). Taxonomic
- 206 classification identified 461 taxa at species level classification. Comparisons of microbial
- 207 metagenomes based on Bray-Curtis Dissimilarity revealed significant divergence (Supplemental
- Figure 1) of community distance between groups (p=0.003,  $R^2 = 0.06$ ) after adjusting for age,

11

BMI, and diet. We compared abundances of individual taxa across groups using the Kruskal-
Wallis test to identify 18 unique and differentially abundant taxa. Highest mean relative
abundances of 14 taxa (Supplemental Table 1) including Dorea sp. CAG:317, Blautia sp.
CAG:257, Ruminococcus gnavus, and Proteobacteria bacterium CAG:139 were observed in
IBS-D, which have previously been linked to mechanisms such as BAM <sup>20, 21</sup> and serotonin
biosynthesis in patients with IBS-D. <sup>41</sup> Lawsonibacter asaccharolyticus abundance was highest in
IBS-C and Firmicutes bacterium CAG:83 abundance was highest in controls.
We followed unadjusted analyses with pairwise comparisons of ALR-transformed taxa
abundances using covariate-adjusted GLM, focusing on high abundant species, to demonstrate
significant differences in 17 pairwise comparisons including 12 unique species (Figure 4) of
which 11 exhibited differential abundances of $\geq$ 3-fold. Among these taxa, we observed
significantly higher abundances of Dorea sp. CAG:317 and Bifidobacterium pseudocatenulatum
in IBS-D compared to IBS-C or controls and higher abundances of Blautia sp. CAG:257, and
Proteobacteria bacterium CAG:139 in IBS-D compared to controls. We found significantly
higher abundances of Clostridium sp. CAG:58 and lower abundances of Firmicutes bacterium
CAG:83 in both IBS-D and IBS-C relative to controls, respectively. Akkermansia muciniphila
and <i>Prevotella copri</i> were increased in IBS-C compared to controls. Differences of $\geq$ 3-fold in
relative abundances among high abundant bacteria were also observed in 151 pairwise
comparisons (Supplemental Table 2) but were not statistically significant after adjustment for
covariates.
Microbe-SCFA associations differ between IBS subtypes and controls: We conducted pCCA on

230 microbiome and SCFA data, conditioned on transit time, to quantify relationships between taxa

abundances and stool SCFA in the overall cohort and within clinical groups. In the overall

cohort, we observed a significant correlation between microbiome abundance matrix and SCFA

232

233	concentration matrix (p=0.033, $R^2 = 0.095$ ). Relationships between microbiome abundances and
234	SCFA concentrations within clinical groups (Supplemental Figure 2) were more pronounced
235	within IBS-D (p=0.015) and less pronounced in HV and IBS-C (p=ns). In the overall cohort,
236	strongest positive associations with total SCFA were observed with Bacteroides plebeius,
237	Prevotella sp. CAG:1031, and Bifidobacterium pseudocatenulatum.
238	Distinct taxa correlate with individual SCFA across clinical subgroups: Keeping in mind that
239	SCFA effects may depend on SCFA type, we ranked bacterial taxa according to their projection
240	scores for individual SCFAs to assess the pattern of associations between bacterial species and
241	SCFA profiles. Bacteria with higher projection scores for individual SCFAs were considered to
242	have stronger associations with those specific SCFAs. Bacteria with projection scores less than
243	0.5 were excluded from the subsequent analysis. In general, the strength and direction of
244	correlations of individual taxa with acetate, butyrate, and propionate differed according to
245	clinical group (Figure 5). No microbes demonstrated consistent patterns of strong correlations
246	with individual SCFA across all three groups. The greatest number of bacteria with strong
247	associations with SCFA were observed in IBS-D, as evidenced by the larger number of bacteria
248	remaining in the ranked list after filtering. Most microbe-SCFA patterns differed between IBS-D
249	and IBS-C and only a few bacterial species including Ruminococcus torques, Coprococcus
250	comes, Clostridium sp. CAG:299, Bacteroides eggerthii, and Adlercreutzia equolifaciens
251	demonstrated consistent associations across both IBS subtypes with acetate and butyrate.
252	In IBS-D, both positive and negative correlations with stool acetate were observed with
253	multiple taxa. Largest negative projections were observed with several bacteria that have
254	previously linked to SCFA production (B. plebeius, Roseburia hominis), <sup>42, 43</sup> dietary

255	polysaccharides and protein utilizers (Firmicutes bacterium CAG:110), <sup>44</sup> starch or
256	fructooligosaccharide degradation (Bifidobacterium adolescentis), fiber fermentation (e.g.
257	<i>Clostridium leptum</i> <sup>45</sup> ), $\beta$ -fructan utilizers (e.g. <i>Roseburia inulinivorans</i> ). <sup>45</sup> Positive projections
258	were observed with Dialister sp. CAG 357, B. pseudocatenulatum, Alistipes species, Prevotella
259	sp. CAG:1031, R. toques, and R. gnavus. In IBS-C, largest negative projections for acetate were
260	observed between abundances of Dorea sp. CAG:317, Lachnospira pectinoschiza, and
261	Prevotella sp. CAG:1031 while the largest positive projections were observed with
262	Streptococcus salivarus, Bacteroides fragilis, and R. torques. In controls, largest negative
263	projections for acetate were observed with B. plebeius, Dialister sp. CAG:357, Bacteroides
264	dorei, and A. muciniphila. The largest positive projection for acetate among controls was
265	observed with Ruminococcus lactaris.
266	Analysis of microbe-butyrate associations in IBS-D demonstrated negative projection
267	scores for butyrate with several bacteria including Ruminococcaceae bacterium D5, Firmicutes
268	bacterium CAG:110, C. leptum, R. hominis, R. inulinivorans, and Lasaccharolyticus. The
269	largest positive projection scores for butyrate were observed with Alistipes species, Prevotella
270	sp. CAG:1031, and R. torques. In IBS-C and controls, patterns of microbe-butyrate associations
271	largely mirrored the patterns of microbe-acetate associations observed within the respective
	•••••••••••••••••••••••••••••••••••••••
272	clinical groups. In addition, a positive relationship between butyrate and <i>Bacteroides</i>
272	clinical groups. In addition, a positive relationship between butyrate and Bacteroides
272 273	clinical groups. In addition, a positive relationship between butyrate and <i>Bacteroides thetaiotaomicron</i> , a well-known human commensal <sup>46, 47</sup> that exhibits the capacity to digest a

277 Bacteroides massiliensis exhibited negative associations in IBS-D with only a few exceptions

14

278 including S. salivarus, for which the largest positive correlation was observed. In contrast, both 279 positive and negative projections for stool propionate were observed in IBS-C; the largest positive scores were observed for Paraprevotella xylaniphila, Phascolarctobacterium 280 281 succinatutens, and P. copri. Among controls, both positive and negative associations with propionate were observed for multiple bacterial taxa. 282 283 Lower number of bacterial species associated with acetate to butyrate ratios in IBS: Since interconversion of SCFA from acetate to butyrate may represent a major route of butyrate 284 formation within the gastrointestinal tract,<sup>48</sup> we examined bacterial relationships with acetate to 285 286 butyrate ratios to identify top taxa associated the metabolic processes that drive SCFA output. 287 The largest positive associations were observed with Prevotella sp. 885, Firmicutes bacterium CAG:83, P. xylaniphila in IBS-D, suggesting that these species were associated with shift toward 288

decreased butyrate production. Unlike the patterns observed with individual SCFA, analysis

acetate to butyrate ratios demonstrated that the number of ranked bacteria were substantially

lower in IBS-D or IBS-C compared to controls (Figure 5), suggesting the possibility of reduced

292 functional redundancy for butyrate formation in IBS.

293 <u>Reduced SCFA-producing microbes and bile acid malabsorption (BAM)</u>: Stool microbial

metagenomes were analyzed in 22 IBS-D patients with (n=8) and without (n=14) clinical BAM

according to previously validated diagnostic cutoff values.<sup>12, 13</sup> Comparisons of beta diversity

based on Euclidian dissimilarity of ALR transformed abundance data showed significant

dissimilarity (p = 0.039;  $R^2 = 0.061$ ) between patients with and without BAM (Supplemental

- Figure 3). Significant differences in six high abundant species were observed between groups,
- 299 including L. asaccharolyticus R. inulinivorans, L. pectinoschiza, and F. saccharivorans which

15

300	were also associated with stool SCFA, but not bile acids, in IBS-D. These four species with
301	known SCFA-producing capacity were negatively correlated with BAM.

#### 302 *Functional potential for carbohydrate degradation, SCFA metabolism, and mucin degradation:*

Examination of microbial gene families and pathways yielded 949,223 total gene families within

the metagenome data set including 4,042 named KO terms. We applied a gut metabolic module

305 (GMM) framework to analyze modules related to carbohydrate degradation, SCFA production or

- metabolism including bacterial cross-feeding pathways, mucin degradation, and one module
- related to serine degradation based on significant species-based predictors. Abundances of KO

identifiers within modules for lactose degradation, (p=0.0026), serine degradation (p=0.019), and

propionate production (p=0.026) were significantly enriched in IBS-C compared to controls.

Relative abundance of a KO identifier within a galactose degradation module was significantly

reduced in IBS-D (p=0.033) compared to controls. In the collective cohort, we applied the GMM

framework to analyze the relationships between metagenomically-encoded functions and stool

313 SCFA. We identified 23, 23, 15, and 16 KO identifiers from relevant GMMs that were

significantly associated with total SCFA, acetate, butyrate, and propionate, respectively. Within a

representative subset (n=6 controls, n=5 IBS-D, n=5 IBS-C) selected by stool form

316 characteristics, functional metagenomic analyses demonstrated that microbial genes/pathways

associated with SCFA production/metabolism and degradation of carbohydrates/ mucin were

differentially associated with clinical group (Figure 6).

#### 319 **DISCUSSION**

It has been proposed that changes in intestinal SCFAs in some patients with IBS are caused by shifts in microbial composition and function to drive and maintain symptoms. We hypothesized that specific features of the GI microbiome may correlate with SCFA output and

16

323 that these relationships may distinguish IBS subtypes and endophenotypes. We further 324 hypothesized that functional features of the GI microbiome defined by substrate preferences and 325 SCFA metabolism may be linked to bowel dysfunction. Using a dual-omics approach, our 326 findings demonstrate microbiota-SCFA relationships differ between IBS subtypes and endophenotypes, and between patients with IBS and healthy controls. We elected to focus on 327 microbe-SCFA relationship due to the established biological relevance of SCFA in GI 328 329 physiology and to use a focused strategy for identifying the microbes involved in shaping the 330 microbial metabolome. Our findings suggest that key taxa may predict IBS mechanisms and that the functional repertoire of the intestinal microbiome influences bowel functions. By capturing 331 quantifiable traits, we also gather evidence suggesting the microbiome has direct effects on 332 excreted SCFA and were able to identify microbe-SCFA relationships that are not explained by 333 transit, to potentially isolate major microbial features (or keystone taxa) that shape SCFA output. 334 While numerous studies have reported compositional changes<sup>11</sup> in IBS such as decreased 335 microbial diversity and altered abundances of individual taxa, consistent patterns are difficult to 336 337 pinpoint and limit our ability to draw actional insights. Recent data suggest that putative 338 microbial biomarkers are related to mechanistic and host-specific features in IBS rather than the overall clinical syndrome. Consistent with these prior studies, we observed differences in overall 339 340 microbial community composition across groups. Comparisons of taxa abundances demonstrated significant changes were most common in IBS-D and predominantly characterized by higher 341 342 abundances of several bacterial species including Blautia sp. CAG:257, R. gnavus, Dorea sp. CAG:317, and Proteobacteria bacterium CAG:139. R. gnavus, a Lachnospiraceae, has 343 previously been identified to play a pathogenic role in IBS-D through serotonin biosynthesis,<sup>41</sup> 344 biofilm formation and increased stool bile acid excretion,<sup>21</sup> production of proinflammatory 345

346	polysaccharides, <sup>49</sup> and mucin degradation. <sup>50</sup> Interestingly, the relationship between <i>R. gnavus</i>
347	and IBS lost its significant in adjusted analyses due to a positive association between R. gnavus
348	and BMI which may suggest a role R. gnavus in explaining the connection between IBS-D or
349	chronic diarrhea with metabolic syndrome and obesity-related disorders although further
350	validation of this hypothesis will be required. <sup>51</sup> Associations of IBS-D with other taxa including
351	Dorea sp. CAG:317, Blautia sp. CAG:257, and Proteobacteria bacterium CAG:139 remained
352	and a new association between B. pseudocatenulatum and IBS-D emerged. In our analyses of
353	microbe-SCFA relationships, strongest contributions to SCFA in the overall cohort were
354	observed with Bacteroides plebeius, Prevotella sp. CAG:1031, and B. pseudocatenulatum
355	suggesting these taxa as major drivers of microbial metabolism which is consistent with their
356	known functions. B. plebeius harbors a specialized polysaccharide utilization locus acquired
357	through horizontal gene transfer from marine bacteria. <sup>52, 53</sup> Prevotella spp. are highly prevalent
358	within the human gut, and is largely regarded as a fiber degrader that is associated with agrarian
359	or plant-based diets, although strain-level variations may impact their contributions to health and
360	disease. <sup>54</sup> B. pseudocatenulatum is recognized as an adult-type Bifidobacterium that is
361	metabolically adapted toward dietary carbohydrates including long-chain xylans. <sup>55</sup> Among the
362	three clinical groups, we found microbe-SCFA associations were most pronounced in IBS-D and
363	that fewer microbes were linked to acetate and butyrate ratios. These observations may indicate
364	that microbial contributions to SCFA profiles are particularly important in IBS-D and may also
365	imply a greater degree of microbial specialization and reduced functional redundancy.
366	Previously, Jacobs et al. <sup>56</sup> reported significant increases in transcript abundances for
367	fructooligosaccharide and polyol utilization and upregulation of transcripts for fructose and
368	glucan metabolism as well as the succinate pathway for carbohydrate fermentation in IBS.

18

369 Comparisons between IBS-D and IBS-C demonstrated differences in microbial metabolism with 370 upregulation of multiple metabolic pathways including transcripts for fructose, mannose, and polyol metabolism in IBS-D. Together, our findings suggest that differences microbial 371 372 metabolism between IBS subtypes may underlie variations in clinical symptoms or that changes in microbial metabolism could play a particularly prominent role in IBS-D. These findings could 373 explain the higher prevalence of mixed- and diarrhea-predominant symptoms in post-infection 374 IBS<sup>57, 58</sup> as well as the limited evidence for efficacy of antimicrobial treatments such as rifaximin 375 in IBS-C<sup>59</sup> relative to IBS-D.<sup>60, 61</sup> 376

377 Dorea sp. CAG:317 and B. pseudocatenulatum were identified as top ranked bacteria 378 associated with acetate to butyrate ratio and acetate concentrations. Mucin degradation has been 379 described among several Dorea species and the genus Dorea belongs to the Lachnospiraceae family, a major producer of SCFA,<sup>62</sup> Notably, Wang et al.<sup>63</sup> recently demonstrated that while 380 381 xylan supplementation following fiber deprivation alleviated gut dysbiosis through selective promotion of B. pseudocatenulatum, these changes were found to be associated with lower 382 383 community diversity. Dorea sp. CAG:317 and B. pseudocatenulatum may represent keystone 384 taxa linked to altered microbial metabolism or persistent impairment in community recovery among patients with IBS-D. Only two bacterial species, A. muciniphila and P. copri were 385 significantly increased in IBS-C. Although relationships between microbes and SCFA were less 386 clear in IBS-C. *P. copri* was further identified as top ranked bacteria that was positively 387 388 associated with propionate and negatively associated with acetate to butyrate ratio in IBS-C. 389 Previous studies have reported increased A. muciniphila in IBS-C to be protective against experimentally-induced colitis in mice<sup>64</sup> and a positive association between mucosal *P. copri* 390 abundance and abdominal pain in patients with IBS without prior history of infection.<sup>65</sup> Others 391

392	have demonstrated that IBS patients with high levels of propionate present with worse
393	gastrointestinal symptoms, quality of life, and negative emotions. <sup>15</sup> P. copri is a prominent gut
394	commensal that contributes to propionate production via the succinate pathway <sup>66</sup> and has been
395	linked to both beneficial and harmful effects on human health. Rolhion et al. found P. copri to be
396	associated with mucus erosion and increased propionate. In another study by Jiang et. al, P. copri
397	colonization was associated with proinflammatory effects following a a high fiber diet in patients
398	with rheumatoid arthritis through succinate production. <sup>67</sup> Exacerbation of rheumatoid with the
399	high fiber diet in the presence of P. copri colonization led to microbial dysbiosis characterized
400	by increased abundance of Akkermansia, which was also increased in our own IBS-C cohort.
401	In addition to identify major microbial features associated with individual SCFA, we
101	
402	made several important observations related to the pattern or direction of observed microbe-
403	SCFA relationships. Interestingly, negative correlations were observed in the IBS-D subgroup
404	between several SCFA-producing species including R. hominis, B. adolescentis, R. inulinivorans
405	and individual SCFA. B. adolescentis utilizes fructo-oligosaccharides and starch and leads to the
406	production of lactate and acetate which is cross-fed to butyrate-producing anaerobes, <sup>68</sup> but have
407	also been identified as a potential GABA producer and correlated with anxiety and/or
408	depression, <sup>69</sup> which are common comorbid conditions in patients with IBS. <i>R. inulinivorans</i> is a
409	known fiber fermenter <sup>45</sup> that also possesses the ability to forage mucin through a metabolic
410	interplay with other members of the intestinal microbiota <sup>70</sup> and is also known for net acetate
411	uptake, <sup>66</sup> which may explain its correlation with reduced SCFA. In general, analysis of bacterial
412	associations with individual SCFAs demonstrated the largest number of negative associations in
413	IBS-D. Many of these negative correlations involved bacterial species that have been implicated
414	in SCFA production and polysaccharide utilization. Findings may imply disrupted cross-feeding

415	mechanisms, modifications in substrate utilization, competitive inhibition, or other context-
416	specific changes leading to altered microbial metabolism in IBS. Upon analyzing relationships of
417	bacterial species with acetate to butyrate ratios, which we studied as a marker for overall SCFA
418	production and intestinal SCFA availability, <sup>71</sup> we identified fewer top ranked bacteria in IBS
419	compared to healthy controls to suggest a reduction in overall functional redundancy within the
420	IBS microbiome. Future work should investigate the effects of bacterial cross-feeding, microbial
421	conversions, and interactions of the colonic microbiome with diet- and host-derived substrates
422	that may destabilize the microbiota-mucosal interface to expose vulnerabilities and promote
423	pathophysiological mechanisms that drive IBS.
424	A few bacterial species were associated with SCFA in both IBS subtypes including <i>R</i> .
425	torques, C. comes, Clostridium sp. CAG:299, B. eggerthii, and Adlercreutzia equolifaciens
426	which may suggest these bacterial species represent shared microbial features across IBS
427	subtypes. R. torques is a mucin-degrading bacteria that has previously been associated with
428	IBS <sup>72</sup> as well as depression. <sup>73</sup> Similarly, recent studies have demonstrated associations between
429	<i>C. comes</i> <sup>74</sup> and <i>B. eggerthii</i> <sup>75</sup> depression and PTSD, which have both been described as
430	comorbid conditions in IBS. R. A. equolifaciens has been described as an anti-inflammatory
431	commensal in non-alcoholic fatty liver disease. <sup>76</sup> These data could point towards shared
432	microbial features as novel biomarker of common pathogenic mechanisms in IBS involving the
433	microbiota-gut-brain axis, possibly through the effects of microbially-derived SCFA.
434	In our comparisons across IBS-D patients by with and without BAM, we observed BAM
435	to be associated with reduced abundances of several SCFA-producing bacterial species. Similar
436	observations have been made in studies linking biofilm formation to bile acid accumulation and
437	reduced SCFA-producing bacteria. <sup>21</sup> Results suggest that BAM exerts indirect effects on the

21

438 intestinal metabolome or the overall metabolic potential of the colonic microbiota characterized 439 by a decline in SCFA-producing capacity. We also assessed of functional variations in the GI microbiome to reveal differential abundances of KO identifiers belonging to metabolic processes 440 441 related to degradation of carbohydrates and serine as well as SCFA production. In a subset of participants selected by stool form characteristics, we identified changes in substrate degradation 442 potential and fermentative capacity between IBS and controls and between IBS subtypes that 443 were characterized by increased capacity for starch degradation in controls, enhancement of 444 distinct mucin-degrading functions in IBS-D vs. IBS-C, and reduced pectin degrading potential 445 446 in IBS-C. Results suggest that abnormal stool form in IBS is influenced by microbiota-encoded substrate preferences. 447 Collectively, our findings indicate there are distinct changes in microbiome composition 448

449 may underlie clinical heterogeneity in IBS. Using a dual-omics approach, we demonstrate that 450 the gut microbiota in IBS-D is characterized by increased metabolic activity, reduced functional 451 redundancy, and persistently reduced diversity. Several taxa including R. gnavus, Dorea sp. 452 CAG:317 and B. pseudocatenulatum are identified as the leading candidates for further study as 453 potential microbial targets in IBS-D. A few unique microbial features including P. copri-454 associated propionate production and Akkermansia expansion may play a crucial role in IBS-C. 455 Meanwhile, microbial features that are common between subtypes may offer insights into shared pathophysiological mechanisms involving the microbiota-gut-brain axis in IBS. Identifying the 456 457 major microbial features (taxa or functions) that drive metabolic output may be crucial in 458 defining rational approaches to modulate the microbiome in IBS.

459 Despite study strengths, we recognize the limitations of this work including cross460 sectional sampling, which overlooks the fluctuating nature of the microbiome. To address this,

22

461 we assessed relationships between microbial abundances and quantifiable IBS endophenotypes 462 that were defined at the time of specimen collection while accounting for baseline covariates. All participants were instructed to consume a 4-day high fat diet while otherwise maintaining their 463 464 usual diet. Previously, we examined the effect of both habitual diet and real-time intake on excreted stool SCFA to find that that modest variations in macronutrient intake including 465 polysaccharides did not exert substantial effects on excreted SCFA.<sup>25, 77</sup> We enrolled patients 466 with opposing IBS phenotypes from both the university clinics and the surrounding communities 467 to increase our ability to detect differences between clinical cohorts and limit referral bias. We 468 469 also acknowledge that causal microbial mechanisms cannot be determined through the current work. However, we applied a dual-omics approach to investigate biologically relevant changes in 470 intestinal microbiome composition and function. Finally, we cannot discount the possibility we 471 472 may have missed significant taxa due to the moderate sample size and a risk for Type I errors as 473 we did not adjust for false discovery rate in our analysis of taxonomic differences. However, our 474 analytic approach was based on endpoints that were determined *a priori* and we applied a 475 conservative strategy by focusing on taxa that were associated with SCFA while accounting for transit. We further limited analyses to high abundant taxa and to species that exhibited >3-fold 476 change in abundance while focusing on the biological plausibility of our results. Findings from 477 this study should be validated in larger, longitudinal cohorts, but provide a framework that may 478 be used to define key microbial interactions and targets in IBS. 479 480 In conclusion, main findings from this study highlight microbiota-SCFA patterns vary 481 across clinical IBS phenotypes and endophenotypes. Our observations suggest that a paired

microbe-metabolite approach may represent a viable strategy for identifying actionable microbial
features in heterogenous patient populations. Prominent shifts in microbial composition are

- 484 observed in IBS-D. These changes appear to affect metabolic capacity, substrate preferences, and
- 485 metabolite profiles. In addition, altered microbial substrate uptake may impact stool form or
- 486 bowel function in IBS. These findings generate new hypotheses regarding candidate microbes
- that could be pursued as actionable microbial biomarkers or metabolically influential features in
- the effort to develop rational microbiota-based therapies in IBS.

24

# 490 **References:**

491	1.	Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of
492		Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.
493		Gastroenterology 2021;160:99-114 e3.
494	2.	Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet
495		2020;396:1675-1688.
496	3.	Tap J, Derrien M, Tornblom H, et al. Identification of an Intestinal Microbiota Signature
497		Associated With Severity of Irritable Bowel Syndrome. Gastroenterology 2017;152:111-
498		123 e8.
499	4.	Anitha M, Vijay-Kumar M, Sitaraman SV, et al. Gut microbial products regulate murine
500		gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology
501		2012;143:1006-16 e4.
502	5.	Heitkemper MM, Cain KC, Shulman RJ, et al. Stool and urine trefoil factor 3 levels:
503		associations with symptoms, intestinal permeability, and microbial diversity in irritable
504		bowel syndrome. Benef Microbes 2018;9:345-355.
505	6.	Sundin J, Rangel I, Repsilber D, Brummer RJ. Cytokine Response after Stimulation with
506		Key Commensal Bacteria Differ in Post-Infectious Irritable Bowel Syndrome (PI-IBS)
507		Patients Compared to Healthy Controls. PLoS One 2015;10:e0134836.
508	7.	McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among
509		epithelium, immunity and microbiota. Cell Microbiol 2001;3:1-11.
510	8.	Liu Y, Zhang L, Wang X, et al. Similar Fecal Microbiota Signatures in Patients With
511		Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Clin
512		Gastroenterol Hepatol 2016;14:1602-1611 e5.

513	9.	Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of
514		IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol
515		Motil 2013;25:e272-82.
516	10.	Mars RAT, Frith M, Kashyap PC. Functional Gastrointestinal Disorders and the
517		Microbiome-What Is the Best Strategy for Moving Microbiome-based Therapies for
518		Functional Gastrointestinal Disorders into the Clinic? Gastroenterology 2021;160:538-
519		555.
520	11.	Pittayanon R, Lau JT, Yuan Y, et al. Gut Microbiota in Patients With Irritable Bowel
521		Syndrome-A Systematic Review. Gastroenterology 2019;157:97-108.
522	12.	Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary
523		and secondary bile acids, and colonic transit in patients with irritable bowel syndrome.
524		Clin Gastroenterol Hepatol 2013;11:1270-1275 e1.
525	13.	Vijayvargiya P, Camilleri M, Burton D, et al. Bile and fat excretion are biomarkers of
526		clinically significant diarrhoea and constipation in irritable bowel syndrome. Aliment
527		Pharmacol Ther 2019;49:744-758.
528	14.	Mars RAT, Yang Y, Ward T, et al. Longitudinal Multi-omics Reveals Subset-Specific
529		Mechanisms Underlying Irritable Bowel Syndrome. Cell 2020;182:1460-1473 e17.
530	15.	Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic
531		acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol
532		Motil 2010;22:512-9, e114-5.
533	16.	Vijayvargiya P, Camilleri M, Chedid V, et al. Analysis of Fecal Primary Bile Acids
534		Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional
535		Diarrhea. Clin Gastroenterol Hepatol 2019;17:922-929 e2.

536	17.	BouSaba J, Sannaa W, McKinzie S, et al. Impact of Bile Acid Diarrhea in Patients With
537		Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life. Clin
538		Gastroenterol Hepatol 2022;20:2083-2090 e1.
539	18.	BouSaba J, Zheng T, Dilmaghani S, et al. Effect of rapid colonic transit on stool
540		microbiome and short-chain fatty acids in diarrhoea-predominant irritable bowel
541		syndrome. Gut 2023.
542	19.	Camilleri M, Carlson P, BouSaba J, et al. Comparison of biochemical, microbial and
543		mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with
544		diarrhoea. Gut 2023;72:54-65.
545	20.	Zhao L, Yang W, Chen Y, et al. A Clostridia-rich microbiota enhances bile acid excretion
546		in diarrhea-predominant irritable bowel syndrome. J Clin Invest 2020;130:438-450.
547	21.	Baumgartner M, Lang M, Holley H, et al. Mucosal Biofilms Are an Endoscopic Feature
548		of Irritable Bowel Syndrome and Ulcerative Colitis. Gastroenterology 2021;161:1245-
549		1256 e20.
550	22.	Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut
551		Microbiota in Gut-Brain Communication. Front Endocrinol (Lausanne) 2020;11:25.
552	23.	Ringel-Kulka T, Choi CH, Temas D, et al. Altered Colonic Bacterial Fermentation as a
553		Potential Pathophysiological Factor in Irritable Bowel Syndrome. Am J Gastroenterol
554		2015;110:1339-46.
555	24.	Gargari G, Taverniti V, Gardana C, et al. Fecal Clostridiales distribution and short-chain
556		fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol
557		2018;20:3201-3213.

558	25.	Waseem MR,	Shin A,	Siwiec I	R, et al.	Associations	of Fecal	Short	Chain Fatt	y Acids
-----	-----	------------	---------	----------	-----------	--------------	----------	-------	------------	---------

- 559 With Colonic Transit, Fecal Bile Acid, and Food Intake in Irritable Bowel Syndrome.
- 560 Clin Transl Gastroenterol 2023;14:e00541.
- 561 26. Deehan EC, Yang C, Perez-Munoz ME, et al. Precision Microbiome Modulation with
- 562Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production. Cell Host
- 563 Microbe 2020;27:389-404 e6.
- 564 27. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016.
- 565 28. Mulligan AA, Luben RN, Bhaniani A, et al. A new tool for converting food frequency
- questionnaire data into nutrient and food group values: FETA research methods and
- 567 availability. BMJ Open 2014;4:e004503.
- Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form
  in the general population: a prospective study. Gut 1992;33:818-24.
- 570 30. Sadik R, Abrahamsson H, Ung KA, Stotzer PO. Accelerated regional bowel transit and
- 571 overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol
- 572 2004;99:711-8.
- 573 31. Park J, Kim M, Kang SG, et al. Short-chain fatty acids induce both effector and
- regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-
- 575 S6K pathway. Mucosal Immunol 2015;8:80-93.
- 576 32. Tagliacozzi D, Mozzi AF, Casetta B, et al. Quantitative analysis of bile acids in human
- 577 plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and
- rapid one-step method. Clin Chem Lab Med 2003;41:1633-41.
- 579 33. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid
- 580 malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013;11:1232-9.

581	34.	Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal
582		cancer. Nat Rev Microbiol 2014;12:661-72.

- 583 35. McMurdie PJ, Holmes S. Phyloseq: a bioconductor package for handling and analysis of
- high-throughput phylogenetic sequence data. Pac Symp Biocomput 2012:235-46.
- 585 36. Oksanen J, Simpson GL, Blanchet F, et al. vegan: Community Ecology Package.
- 586 Ordination methods, diversity analysis and other functions for community and vegetation 587 ecologists. 2.6-4 ed, 2022.
- 588 37. Vieira-Silva S, Falony G, Darzi Y, et al. Species-function relationships shape ecological
  589 properties of the human gut microbiome. Nat Microbiol 2016;1:16088.
- 590 38. Vujkovic-Cvijin I, Sklar J, Jiang L, et al. Host variables confound gut microbiota studies
  591 of human disease. Nature 2020;587:448-454.
- 592 39. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-gut
- and colonic transit? Results from a multicenter study in constipated individuals and
- healthy controls. Am J Gastroenterol 2010;105:403-11.
- 595 40. Jaruvongvanich V, Patcharatrakul T, Gonlachanvit S. Prediction of Delayed Colonic
- 596 Transit Using Bristol Stool Form and Stool Frequency in Eastern Constipated Patients: A
- 597 Difference From the West. J Neurogastroenterol Motil 2017;23:561-568.
- 598 41. Zhai L, Huang C, Ning Z, et al. Ruminococcus gnavus plays a pathogenic role in
- diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis. Cell
  Host Microbe 2023;31:33-44 e5.
- 42. Yun EJ, Yu S, Park NJ, et al. Metabolic and enzymatic elucidation of cooperative
- degradation of red seaweed agarose by two human gut bacteria. Sci Rep 2021;11:13955.

603	43.	Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species
604		Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with
605		ulcerative colitis. Gut 2014;63:1275-83.
606	44.	Quan J, Wu Z, Ye Y, et al. Metagenomic Characterization of Intestinal Regions in Pigs
607		With Contrasting Feed Efficiency. Front Microbiol 2020;11:32.
608	45.	Armstrong HK, Bording-Jorgensen M, Santer DM, et al. Unfermented beta-fructan Fibers
609		Fuel Inflammation in Select Inflammatory Bowel Disease Patients. Gastroenterology
610		2023;164:228-240.
611	46.	Martens EC, Chiang HC, Gordon JI. Mucosal glycan foraging enhances fitness and
612		transmission of a saccharolytic human gut bacterial symbiont. Cell Host Microbe
613		2008;4:447-57.
614	47.	Porter NT, Luis AS, Martens EC. Bacteroides thetaiotaomicron. Trends Microbiol
615		2018;26:966-967.
616	48.	Shetty SA, Boeren S, Bui TPN, et al. Unravelling lactate-acetate and sugar conversion
617		into butyrate by intestinal Anaerobutyricum and Anaerostipes species by comparative
618		proteogenomics. Environ Microbiol 2020;22:4863-4875.
619	49.	Henke MT, Kenny DJ, Cassilly CD, et al. Ruminococcus gnavus, a member of the human
620		gut microbiome associated with Crohn's disease, produces an inflammatory
621		polysaccharide. Proc Natl Acad Sci U S A 2019;116:12672-12677.
622	50.	Bell A, Brunt J, Crost E, et al. Elucidation of a sialic acid metabolism pathway in mucus-
623		foraging Ruminococcus gnavus unravels mechanisms of bacterial adaptation to the gut.
624		Nat Microbiol 2019;4:2393-2404.

625	51.	Shin A, Xu H, Imperiale TF. Associations of chronic diarrhoea with non-alcoholic fatty
626		liver disease and obesity-related disorders among US adults. BMJ Open Gastroenterol
627		2019;6:e000322.
628	52.	Hehemann JH, Correc G, Barbeyron T, et al. Transfer of carbohydrate-active enzymes
629		from marine bacteria to Japanese gut microbiota. Nature 2010;464:908-12.
630	53.	Hehemann JH, Kelly AG, Pudlo NA, et al. Bacteria of the human gut microbiome
631		catabolize red seaweed glycans with carbohydrate-active enzyme updates from extrinsic
632		microbes. Proc Natl Acad Sci U S A 2012;109:19786-91.
633	54.	De Filippis F, Pasolli E, Tett A, et al. Distinct Genetic and Functional Traits of Human
634		Intestinal Prevotella copri Strains Are Associated with Different Habitual Diets. Cell
635		Host Microbe 2019;25:444-453 e3.
636	55.	Derrien M, Turroni F, Ventura M, van Sinderen D. Insights into endogenous
637		Bifidobacterium species in the human gut microbiota during adulthood. Trends Microbiol
638		2022;30:940-947.
639	56.	Jacobs JP, Lagishetty V, Hauer MC, et al. Multi-omics profiles of the intestinal
640		microbiome in irritable bowel syndrome and its bowel habit subtypes. Microbiome
641		2023;11:5.
642	57.	Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of
643		Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-
644		analysis. Gastroenterology 2017;152:1042-1054 e1.
645	58.	Breen-Lyles M, Decuir M, Byale A, et al. Impact of Rome IV criteria on the prevalence
646		of post-infection irritable bowel syndrome. Neurogastroenterol Motil 2023;35:e14532.

- 59. Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant
  irritable bowel syndrome. Dig Dis Sci 2014;59:1278-85.
- 649 60. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable
- bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
- 651 61. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the
- 652 Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
- 653 Gastroenterology 2022;163:137-151.
- 654 62. Vacca M, Celano G, Calabrese FM, et al. The Controversial Role of Human Gut
- Lachnospiraceae. Microorganisms 2020;8.
- 656 63. Wang Z, Bai Y, Pi Y, et al. Xylan alleviates dietary fiber deprivation-induced dysbiosis
- by selectively promoting Bifidobacterium pseudocatenulatum in pigs. Microbiome2021;9:227.
- 659 64. Gobert AP, Sagrestani G, Delmas E, et al. The human intestinal microbiota of
- 660 constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory
- 661 properties. Sci Rep 2016;6:39399.
- 662 65. Choo C, Mahurkar-Joshi S, Dong TS, et al. Colonic mucosal microbiota is associated
- with bowel habit subtype and abdominal pain in patients with irritable bowel syndrome.
- Am J Physiol Gastrointest Liver Physiol 2022;323:G134-G143.
- 665 66. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic
  666 microbiota. Environ Microbiol 2017;19:29-41.
- 667 67. Jiang L, Shang M, Yu S, et al. A high-fiber diet synergizes with Prevotella copri and
- exacerbates rheumatoid arthritis. Cell Mol Immunol 2022;19:1414-1424.

669	68.	Belenguer A, Duncan SH, Calder AG, et al. Two routes of metabolic cross-feeding
670		between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human
671		gut. Appl Environ Microbiol 2006;72:3593-9.
672	69.	Duranti S, Ruiz L, Lugli GA, et al. Bifidobacterium adolescentis as a key member of the
673		human gut microbiota in the production of GABA. Sci Rep 2020;10:14112.
674	70.	Pichler MJ, Yamada C, Shuoker B, et al. Butyrate producing colonic Clostridiales
675		metabolise human milk oligosaccharides and cross feed on mucin via conserved
676		pathways. Nat Commun 2020;11:3285.
677	71.	Wijdeveld M, Schrantee A, Hagemeijer A, et al. Intestinal acetate and butyrate
678		availability is associated with glucose metabolism in healthy individuals. iScience
679		2023;26:108478.
680	72.	Carco C, Young W, Gearry RB, et al. Increasing Evidence That Irritable Bowel
681		Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis.
682		Front Cell Infect Microbiol 2020;10:468.
683	73.	Mulder D, Jakobi B, Shi Y, et al. Gut microbiota composition links to variation in
684		functional domains across psychiatric disorders. Brain Behav Immun 2024;120:275-287.
685	74.	Yu L, Chen X, Bai X, et al. Microbiota Alters and Its Correlation with Molecular
686		Regulation Underlying Depression in PCOS Patients. Mol Neurobiol 2023.
687	75.	Xiao L, Liu S, Wu Y, et al. The interactions between host genome and gut microbiome
688		increase the risk of psychiatric disorders: Mendelian randomization and biological
689		annotation. Brain Behav Immun 2023;113:389-400.

	690	76.	Onate FP, Chamignon	C, Burz SD, et al.	. Adlercreutzia equolifaciens Is	s an Anti-
--	-----	-----	---------------------	--------------------	----------------------------------	------------

- 691 Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of
- 692 Patients with Metabolic Liver Disease. Int J Mol Sci 2023;24.
- 693 77. Calderon G, Patel C, Camilleri M, et al. Associations of Habitual Dietary Intake With
- 694 Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. J Clin
- 695 Gastroenterol 2022;56:234-242.

696

- 697
- 698

34

Data show mean (standard deviation	Controls (n=17)	IBS-C	IBS- D
[SD]) except where specified		(n=15)	( <b>n=26</b> )
Age (years)	31.7 (13.6)	34.3 (10.5)	38.7 (15.3)
Women, n (%)	12 (71%)	13 (87%)	18 (70%)
<b>BMI</b> , $kg/m^2$	26.3 (5.9)	25.3 (5.2)	26.7 (9.4)
White, n (%)	9 (53%)	10 (67%)	23 (88%)
<b>Baseline dietary intake*</b>			
Energy (kcal)	1946.8 (1025.7)	2028.4 (1717.3)	1514.1 (557.4)
Total carbohydrates (g)	219.4 (155.6)	191.1 (153.7)	160.1 (62.9)
Starch (g)	104.7 (54.9)	107.9 (110.9)	87.7 (46.9)
Protein (g)	100.9 (47.1)	96.8 (75.3)	75.1 (23.4)
Fat (g)	77.6 (34.7)	99.6 (101.9)	63.8 (30.3)
Fiber (g)	17.9 (20.9)	14.3 (10.0)	11.6 (4.1)

700 **Table 1:** Clinical Characteristics of Patients with Irritable Bowel Syndrome (IBS) and Controls

701 Group comparisons were conducted using the ANOVA F- and Fisher exact tests. IBS-C, IBS with

702 constipation; IBS-D, IBS with diarrhea; \*Diet data missing for two participants with IBS-C and

703 four participants with IBS-D

2	5
0	3

Data show median (interquartile range)	Controls	IBS-C	IBS- D
Data show meatan (interquartite range)			
	( <b>n=17</b> )	(n=15)	( <b>n=26</b> )
Total stool bile acids (µmol/48h)* <sup>#\$</sup>	342 (130-640)	190 (110-449)	607 (447-1235)
Primary stool bile acids (%)	2.1 (0.8-9.1)	1.8 (0.8-2.4)	3.1 (0.8-12.4)
Total stool SCFA (µg/mg) <sup>@**</sup>	9.8 (4.5-13.8)	11.6 (7.7-20.0)	14.3 (10.0-20.8)
Stool acetate <sup>@*</sup>	6.3 (3.3-8.5)	7.1 (5.3-12.8)	9.4 (5.9-14.1)
Stool propionate	1.7 (0.8-2.4)	2.2 (1.5-2.9)	2.4 (1.6-4.0)
Stool butyrate	1.2 (0.5-2.4)	2.2 (1.0-3.7)	1.9 (1.0-3.6)
Acetate to butyrate ratio	5.0 (3.3-6.7)	3.7 (2.7-4.9)	4.5 (3.3-6.7)
Total colonic transit time (CTT), days	1.4 (0.2-2.5)	1.5 (1.0-2.1)	0.9 (0.5-1.5)
Right CTT, days	0.6 (0.3-0.6)	0.4 (0.2-0.8)	0.4 (0.2-0.6)
Transverse CTT, days	0.1 (0-0.4)	0.3 (0-0.8)	0.1 (0-0.3)
Left CTT, days** <sup>#</sup>	0.5 (0.3-1.9)	0.5 (0.2-1.1)	0.3 (0.1-0.5)

**Table 2:** Quantitative Traits in Patients with Irritable Bowel Syndrome (IBS) and Controls

706 *IBS-C=IBS with constipation; IBS-D=IBS with diarrhea; SCFA=short chain fatty acids.* 

707 *Comparisons across groups were conducted using the Kruskal-Wallis test. For traits showing* 

significant differences (\*p<0.05; \*\*p=0.05), pairwise comparisons were conducted with Dunn's

test, applying Bonferroni correction for multiple tests. p < 0.05 for Controls vs. IBS-D; p = 0.001

for IBS-C vs. IBS-D; all other pairwise comparisons were non-significant (e.g., IBS-C vs.

711 controls); @\*p < 0.05 for Controls vs. IBS. @\*\*p = 0.05 for Controls vs. IBS


## 713 FIGURE LEGENDS


### 714 **Figure 1:** Consort Flow Diagram

- **Figure 2:** Stool Short Chain Fatty Acid Concentrations in Healthy Volunteers and Participants
- with Irritable Bowel Syndrome (IBS). *Histograms are shown for total short chain fatty acids*,
- 717 acetate, butyrate, propionate, and acetate to butyrate ratios within clinical groups including
- 718 *healthy volunteers (HV), IBS with constipation (IBS-C), and IBS with diarrhea (IBS-D). Groups*
- 719 *are denoted by color (HV = red, IBS-C = green, IBS-D = blue).*
- **Figure 2:** Stool Bile Acids in Healthy Volunteers and Participants with Irritable Bowel
- Syndrome (IBS). *Histograms are shown for % primary bile acids (bile.acids) and total bile acids*
- within clinical groups including healthy volunteers (HV), IBS with constipation (IBS-C), and IBS
- 723 with diarrhea (IBS-D). Groups are denoted by color (HV = red, IBS-C = green, IBS-D = blue).
- **Figure 4:** Bacterial Taxa with Differential Abundance of  $\geq$ 3-fold Between Groups. *Data show*
- *mean percent abundances (standard deviation) of significantly different bacterial taxa with*  $\geq$ *3-*
- *fold differences in pairwise comparisons of clinical cohorts.*
- **Figures 5:** Correlations of bacterial taxa with short chain fatty acids (SCFA) based on partial
- canonical correspondence analysis. Panels show associations between bacterial taxa and specific
- *SCFA*([*a*] acetate, [*b*] butyrate, [*c*] propionate, and [*d*] and acetate to butyrate ratio) within
- cohorts. The strength of the correlation is represented projections >0.5 with purple indicating
- 731 *negative correlations and red indicating positive correlations.*
- **Figure 6:** Variations in Microbial Substrate Utilization in Healthy Volunteers and Participants
- with IBS. Figure shows significant differences in functional potential for carbohydrate
- 734 degradation, short chain fatty acid production or metabolism, and mucin degradation across


- 735 clinical groups in representative subset selected by stool form characteristics. Groups are
- 736 *denoted by color (HV = blue, IBS-C = red, IBS-D = gray).*


737






Histograms with Density Curves by Cohort






Histograms with Density Curves by Cohort




Histograms with Density Curves by Cohort

Type.of.IBS


HV IBS – C IBS – D






Histograms with Density Curves by Cohort


HV




Mean percent abundances (standard deviation) of significantly different high abundant bacterial taxa in pairwise comparisons						
Таха	Controls	IBS-C	IBS-D	IBS-C vs. Controls (p-value)	IBS-D vs. Controls (p-value)	IBS-C vs. IBS-D (p-value)
Akkermansia muciniphila	0.294 (±1.022)	1.890 (±3.138)	1.241 (±2.676)	0.029	ns	ns
Bifidobacterium pseudocatenulatum	0.064 (±0.167)	0.041 (±0.154)	1.510 (±6.706)	ns	0.034	0 .006
Blautia sp. CAG:257*	0.016 (±0.034)	0.043 (±0.122)	0.121 (±0.220)	ns	0.03	ns
Clostridium sp. CAG:58*	0.013 (±0.022)	0.174 (±0.201)	0.253 (±0.546)	0.004	0.025	ns
Dorea sp. CAG:317*	0.008 (±0.025)	0.006 (±0.025)	0.132 (±0.306)	ns	0.03	0.011
Firmicutes bacterium CAG:110	0.273 (±0.519)	0.030 (±0.096)	0.037 (±0.110)	0.047	ns	ns
Firmicutes bacterium CAG:83*	1.046 (±3.048)	0.135 (±0.185)	0.551 (±1.845)	ns	0.002	0.038
Monoglobus pectinilyticus**	0.164 (±0.540)	0.198 (±0.303)	0.081 (±0.374)	0.028	ns	0.008
Prevotella copri	2.037 (±5.027)	8.401 (±19.932)	3.986 (±12.817)	0.049	ns	ns
Proteobacteria bacterium CAG:139*	0.020 (±0.036)	0.364 (±0.810)	0.635 (±1.512)	ns	0.008	ns
Ruminococcus torques	3.299 (±5.879)	0.755 (±1.570)	0.971 (±1.683)	ns	0.044	ns
Streptococcus salivarius	0.092 (±0.230)	0.121 (±0.177)	0.200 (±0.343)	0.021	ns	ns

\*bacterial species that were significantly different in overall comparisons; \*\* differential increase in M. pectinilyticus abundance in IBS-C vs. controls or IBS-D <3-fold; color scheme represents relative abundance with higher values noted in darker blue







Cohort

Heatmap for Propionic.Acid



